-
With strength, Hengrui applied for four new drugs of category 1.1 in 2014
Time of Update: 2015-01-06
Shr7390 tablets of Hengrui medicine were undertaken by CDE on December 31, 2014 and entered the evaluation center However, the relevant information of shr7390 is not available at present As the leadin
-
Big statistics of CDE drug registration data in 2014
Time of Update: 2015-01-06
I new declaration 1 Statistics by drug type (1) explanation of traditional statistical caliber If it is not described below, "chemical drugs" includes two parts: preparation and raw materials It can b
-
The application of 3 kinds of anticoagulant of Hisilicon for yidusaban tablets of p-toluenesulfonate was accepted
Time of Update: 2015-01-06
Edoxaban is a small molecule oral anticoagulant developed by Japan's first three Co., Ltd., which is an inhibitor of clotting factor X (FXa) and went on the market in April 2011 It can prevent VTE aft
-
Important breakthrough in new drug development of Rongchang ADC
Time of Update: 2015-01-04
ADC（antibody-drug Conjugates, i.e antibody drug conjugates, are formed by the coupling of monoclonal antibodies and small molecule drugs (cytotoxins) The mechanism of action is to specifically identi
-
Application for clinical trial of corynet for injection of Xiangxue pharmaceutical 1.1 new drug was accepted
Time of Update: 2015-01-01
Xiangxue pharmaceutical announced in the evening of December 31, 2014 that the company's application for clinical trials of ketlani for injection was accepted by Guangdong food and drug administration
-
List of major projects of China's new drugs and technology trade in 2014
Time of Update: 2014-12-31
2014 will be gone This year, Chinese pharmaceutical companies have handed over 25 projects in the field of new drugs and technology transactions, five more than last year, as of December 29 There are
-
The production approval of the new drug xidaban
Time of Update: 2014-12-30
Sidabamide, a new class 1.1 drug of Shenzhen microcellular organism, has completed the on-site inspection, and its processing status was changed to "approved pending certification" on December 24, 201
-
Ma Yinglong Pharmaceutical Co., Ltd. cooperates with comadico to develop a new class of pratestosterone sulfate sodium tablets
Time of Update: 2014-12-30
At present, pharmacy, pharmacodynamics, phase I and phase II clinical studies have been completed, and supplementary clinical studies are under way According to the contract, the rights and interests
-
Two new antitumor drugs of Yasheng medicine have obtained clinical approval
Time of Update: 2014-12-29
It is reported that this is the first two clinical research approval documents of original new drugs approved by Taizhou pharmaceutical high tech Zone since its establishment It also marks that Taizho
-
New indication of TACE gazyva chronic lymphocytic leukemia approved by FDA
Time of Update: 2014-12-29
Roche's gene tech recently announced that the U.S FDA approved gazyva's application for a supplementary biologics license (SBLA), which allows gazyva to be combined with nitrogen mustard benzoate for
-
Five year review of Chinese drug approvals 2010-2014
Time of Update: 2014-12-27
Title: as you know in fashion, one day you are in, and the next day you are out! "Is often said by the host of American reality show project runway on the program I think that this sentence is also su
-
2010-2014 approved clinical approval statistics
Time of Update: 2014-12-27
I The Research on the relationship between the application year and the year of approval of clinical approval can be seen from table 1 that there is a normal distribution between the application year
-
New drug approval in 2013 released by CFDA
Time of Update: 2014-12-26
In 2013, there were 4875 manufacturers of APIs and preparations in China; in 2013, 148 new drugs were approved for clinical use, 4 new drug certificates, 66 approval numbers and 45 new drug certificat
-
Suzhou Industrial Park Pharmaceutical Technology Alliance Association established
Time of Update: 2014-12-24
On December 23, the association of pharmaceutical science and technology alliance of Suzhou Industrial Park was officially established, attracting the first batch of more than 30 units to join In the
-
Humanwell pharmaceutical's new class 1.1 drug, propofol sodium, was approved again
Time of Update: 2014-12-23
Propofol sodium is used for intravenous induction during general anesthesia, which is the prodrug of propofol and has stronger sedative effect Insight database shows that humanwell pharmaceutical has
-
Hanyu pharmaceutical has completed technical review and on-site inspection of enkephalin
Time of Update: 2014-12-23
Previously, Yuan Jiancheng, President of Hanyu pharmaceutical, said at the shareholders' meeting that the company's heavyweight new drug enkephalin will follow the academic marketing route after it go
-
Policresulen Gel, a new gynecologic new drug, was approved by Shuanghe pharmaceutical company.
Time of Update: 2014-12-23
Polyphenol sulfonphen is a marketed variety of Huarun Shuanghe, which is mainly used for treating cervicitis, vulva pruritus, cervical polyps, etc the gel used by the company is a new dosage form of p
-
The first Ebola vaccine in China has been approved for clinical research of military special drugs
Time of Update: 2014-12-19
December 18 Recently, the PLA Academy of Military Medical Sciences announced that the "recombinant Ebola virus vaccine" jointly developed by its affiliated Institute of bioengineering and Tianjin kang
-
Qizheng Tibetan medicine, a new anticancer drug, ethane Selene dispersible tablet, has been applied for phase II clinical acceptance
Time of Update: 2014-12-18
According to the public data, ethane Selene is intended to be used for cancer treatment, and the first indication is gastrointestinal cancer and lung cancer, with emphasis on adenocarcinoma, which has
-
Hengrui's new anticancer drug Etan (apatinib) was launched on December 13
Time of Update: 2014-12-15
At the scene of aitan China listing meeting, the launching ceremony of aitan China listing meeting, i.e apatinib mesylate, is the only oral preparation targeted for advanced gastric cancer at present,
